2023 Federal Budget – Impact on Medical Doctors Regarding Surplus Stripping (Capital Gain Strip)

The 2023 Federal Budget has introduced changes that may significantly affect physicians, especially concerning surplus stripping transactions. Here’s a concise overview of the topic and the implications of the recent tax announcements: 

Understanding Surplus Stripping: Physicians often require personal funds for various needs, such as buying a house, paying off a mortgage, or covering personal expenses. Traditionally, many have used surplus-stripping transactions to structure payments from their professional corporations as capital gains instead of dividends. This approach allows them to benefit from a lower tax rate on capital gains (up to 26.76%) compared to taxable dividends (up to 47.74%). By doing so, physicians could achieve tax savings of roughly 15-20% on the amount withdrawn from their professional corporation. For instance, on a surplus strip amount of $1,000,000, the potential tax savings could range between $150,000 to $200,000. 

However, these transactions have always carried some risk. The Income Tax Act has provisions like the general anti-avoidance rule (GAAR) in section 245 and specific anti-surplus-stripping provisions in section 84.1. While the GAAR aims to prevent abusive tax avoidance transactions, section 84.1 targets specific non-arms length surplus stripping strategies, leading to deemed dividend treatment for those affected. 

Historically, Canadian courts have generally opined that the Income Tax Act doesn’t inherently oppose surplus stripping. In cases where GAAR was applicable, the legislative provisions typically aimed to apply only the “reasonable” tax consequences to the taxpayer, essentially nullifying the tax benefit they sought. Some physicians opted for these transactions, weighing the costs, benefits, and inherent risks. 

Changes Introduced in the 2023 Budget: The Federal Budget of 2023, announced on March 28, 2023, unveiled draft legislation related to GAAR. The proposed changes include: 

• Introducing a preamble to the GAAR. 
• Modifying the avoidance transaction standard. 
• Introducing an economic substance rule. 
• Implementing a penalty equivalent to 25% of the tax benefit. 

• Extending the reassessment period by three years. 

These new GAAR rules are set to apply to transactions occurring on or after January 1, 2024. 

Furthermore, the Finance Release on August 4, 2023, provided updated draft legislation with explanatory notes. One of the examples cited in these notes was a surplus strip transaction, which was described as lacking economic substance. However, it’s crucial to note that the Finance department didn’t explicitly state that such a transaction would be caught by the GAAR. Given these changes, physicians are advised to reassess the costs, benefits, and risks of surplus stripping transactions under the revised GAAR legislation.